Kairos Pharma Ltd. (NYSE American: KAPA) has unveiled promising preclinical data for its investigational drug, KROS101, at the ASCO 2025 Annual Meeting. The study highlights KROS101's dual mechanism of action, which not only enhances the activity of effector T cells but also reduces the number of immune-suppressive T reg cells, a combination that could significantly improve cancer immunotherapy outcomes. The data presented showed KROS101's superior performance compared to TRX518, a previous anti-GITR antibody, in promoting tumor infiltration, enhancing cytotoxicity, and preventing T cell exhaustion.
Dr. John Yu, CEO of Kairos Pharma, emphasized the importance of these findings, noting KROS101's potential to revolutionize cancer treatment by simultaneously stimulating the immune system to attack tumors and overcoming immune suppression. This development is particularly noteworthy as it addresses a critical challenge in oncology: the ability of cancers to evade the immune system, leading to treatment resistance and disease progression.
The implications of KROS101's success in preclinical studies are vast, offering hope for more effective treatments for patients with various types of cancer. As Kairos Pharma continues to advance KROS101 through the development pipeline, the oncology community watches closely, anticipating the potential for this small molecule GITR ligand agonist to set a new standard in cancer immunotherapy.
